Lung cancer (NSCLC)

Non-small cell lung cancer (NSCLC) is a common and serious type of lung cancer that affects many people worldwide, making it crucial to understand its complexities for effective treatment.

Advanced studies have revealed significant insights into NSCLC, including the identification of tumor heterogeneity and the role of specific genes like SMARCA4 in disease progression. Research also highlights the importance of immune system interactions within tumors, particularly how PD-L1 signaling can suppress immune responses through myeloid-derived suppressor cells. Additionally, genetic mutations such as EGFR have been linked to the development and behavior of NSCLC, influencing treatment approaches.

Key connections involve genetics, immunology, and personalized medicine, reflecting the multifaceted nature of this disease. Understanding these aspects helps in developing targeted therapies tailored to individual patients.

While studies provide valuable information, more research is needed to fully understand all mechanisms involved in NSCLC.

Sources

• Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. (PMID:33953163)
• Toward personalized treatment approaches for non-small-cell lung cancer. (PMID:34385702)
• SMARCA4: Current status and future perspectives in non-small-cell lung cancer. (PMID:36450331)
• Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer. (PMID:40050048)
• Abandoning the Notion of Non-Small Cell Lung Cancer. (PMID:31155338)
• EGFR mutations and lung cancer. (PMID:20887192)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._